Application of HPLC-ICP-MS to speciation of cisplatin and its degradation products in water containing different chloride concentrations and in human urine

被引:70
作者
Hann, S
Koellensperger, G
Stefánka, Z
Stingeder, G
Fürhacker, M
Buchberger, W
Mader, RM
机构
[1] BOKU Univ Nat Resources & Appl Life Sci, Inst Chem, A-1190 Vienna, Austria
[2] Szent Istvan Univ, Dept Appl Chem, H-1118 Budapest, Hungary
[3] BOKU Univ Nat Resources & Appl Life Sci, Dept Sanit Engn & Water Pollut Control, A-1190 Vienna, Austria
[4] Johannes Kepler Univ Linz, Dept Analyt Chem, A-4040 Linz, Austria
[5] Univ Vienna, Sch Med, Div Oncol, A-1090 Vienna, Austria
关键词
D O I
10.1039/b309028k
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Cisplatin, mono- and diaquacisplatin were measured in aquatic samples and in diluted urine of a cancer patient by HPLC-ICP-MS. On-line IDMS was applied for accurate, species unspecific quantification. Limits of detection of 0.74, 0.69 and 0.65 mug L-1 (3 s criterion) were calculated for cisplatin, monoaqua- and diaquacisplatin, respectively. Degradation kinetics of 6x10(-6) M cisplatin were determined over a period of 48 h in solutions containing 100, 50 and 0 mg L-1 chloride, showing the suitability of the HPLC-ICP-MS method for kinetic model studies. The first order rate constants k(1) of cisplatin aquation for the three chloride concentrations were 1.79x10(-5), 1.68x10(-5) and 2.06x10(-5) s(-1). For cisplatin anatation (second order reverse reaction), rate constants of k(-1)=6.5x10(-3), 5.8x10(-3) and 4.1x10(-3) M-1 s(-1) could be assessed. At low chloride levels, no equilibrium was established between cisplatin and its degradation products. It was found that the intermediately formed mono- and diaquacisplatin-products started to decay after several hours. Diluted urine of a cancer patient contained the parent drug cisplatin and a considerable fraction of highly active monoaquacisplatin, as well as several unknown platinum species.
引用
收藏
页码:1391 / 1395
页数:5
相关论文
共 25 条
[1]  
Berners-Price SJ, 2000, CANC DRUG DISC DEV, V7, P3
[2]   HYDROLYSIS PRODUCTS OF CISPLATIN - PKA DETERMINATIONS VIA [H-1, N-15] NMR-SPECTROSCOPY [J].
BERNERSPRICE, SJ ;
FRENKIEL, TA ;
FREY, U ;
RANFORD, JD ;
SADLER, PJ .
JOURNAL OF THE CHEMICAL SOCIETY-CHEMICAL COMMUNICATIONS, 1992, (10) :789-791
[3]   Slowing of cisplatin aquation in the presence of DNA but not in the presence of phosphate: Improved understanding of sequence selectivity and the roles of monoaquated and diaquated species in the binding of cisplatin to DNA [J].
Davies, MS ;
Berners-Price, SJ ;
Hambley, TW .
INORGANIC CHEMISTRY, 2000, 39 (25) :5603-5613
[4]   CISPLATIN, TRANSPLATIN, AND THEIR HYDRATED COMPLEXES - SEPARATION AND IDENTIFICATION USING POROUS GRAPHITIC CARBON AND ELECTROSPRAY-IONIZATION MASS-SPECTROMETRY [J].
EHRSSON, HC ;
WALLIN, IB ;
ANDERSSON, AS ;
EDLUND, PO .
ANALYTICAL CHEMISTRY, 1995, 67 (19) :3608-3611
[5]   HPIC-UV-ICP-SFMS study of the interaction of cisplatin with guanosine monophosphate [J].
Hann, S ;
Zenker, A ;
Galanski, M ;
Bereuter, TL ;
Stingeder, G ;
Keppler, BK .
FRESENIUS JOURNAL OF ANALYTICAL CHEMISTRY, 2001, 370 (05) :581-586
[6]  
Heudi O, 1999, BIOPHARM DRUG DISPOS, V20, P107, DOI 10.1002/(SICI)1099-081X(199903)20:2<107::AID-BDD161>3.3.CO
[7]  
2-S
[8]   Kinetic studies of the reactivity between cisplatin and its monoaquo species with L-methioniae [J].
Heudi, O ;
Cailleux, A ;
Allain, P .
JOURNAL OF INORGANIC BIOCHEMISTRY, 1998, 71 (1-2) :61-69
[9]   Interactions between cisplatin derivatives and mobile phase during chromatographic separation [J].
Heudi, O ;
Cailleux, A ;
Allain, P .
CHROMATOGRAPHIA, 1997, 44 (1-2) :19-24
[10]  
Heudi O, 2001, INT J CLIN PHARM TH, V39, P344